Graegis Pharmaceuticals Limited
- Address
- The Dorothy Hodgkin Building, Babraham Research Campus, Babraham
Sponsor Overview
Specializations
Radiation-induced dermatitis
Clinical research in radiodermatitis centers on skin reactions associated with radiotherapy, with attention to prevention of treatment-related cutaneous injury in patients receiving breast cancer radiation care.
- Radiotherapy-associated skin toxicity
- Radiation dermatitis prevention
- Cutaneous adverse effects
The sponsor’s activity in this area is linked to supportive care for individuals undergoing adjuvant breast irradiation, with interest in protecting skin integrity during cancer treatment.
Breast cancer supportive care
Research activity extends to supportive management for localised, non-metastatic breast cancer after lumpectomy, where maintaining treatment tolerability is an important clinical concern.
- Post-surgical breast cancer care
- Adjuvant radiation support
- Skin protection during cancer therapy
Interest in this field reflects a focus on patient comfort and preservation of skin health during the course of breast-conserving treatment.
Dermatologic treatment development
The sponsor’s therapeutic interest includes cutaneous gel development for managing treatment-related skin conditions, with emphasis on topical approaches used in oncology-related dermatology.
- Topical skin therapies
- Dermatologic supportive treatments
- Barrier and skin-care interventions
This area connects pharmaceutical research with skin-focused care in patients exposed to radiation therapy.
Oncology symptom management
Clinical interest also lies in reducing treatment-related symptoms that arise during cancer care, particularly those affecting the skin and local tissue response in breast oncology.
- Supportive oncology
- Treatment-related skin reactions
- Patient tolerability
Work in this domain is relevant to improving the management of adverse effects associated with radiation therapy.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Evaluation of GR1014 Cutaneous Gel for Prevention of Radiodermatitis in Patients Undergoing Adjuvant Radiotherapy for Localized Breast Cancer |  France | Not Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 1 is not being studied by other sponsors.
This sponsor has worked with 4 sites across their trial portfolio.
Therapeutic Focus
- 1.Skin and Connective Tissue Diseases1 trial247 other sponsors
Partnered Research Centres
4 centres- Address
- 28 Rue Laennec, 69008 Lyon
- Address
- 5 Avenue Etienne Francois De Choiseul, 56100 Lorient
- Address
- 26 Rue D Ulm, 75005 Paris
- Address
- 114 Rue Edouard Vaillant, 94805 Villejuif
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Graegis Pharmaceuticals Limited.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.